Furthermore, even with attenuated HER2 expression in HR+/HER2-low breast cancer, the intricate interplay of HER2-associated pathways requires thorough consideration while investigating the mechanisms of resistance to CDK4/6 inhibitors in combination with endocrine therapy, thereby unveiling the complex landscape of treatment response16,17. This evidence concerns the gene ERBB2 and breast cancer.